Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 12.95B 11.37B 10.48B 9.8B 18.37B 1,222B 18.71B 126B 48.69B 602B 48.62B 47.55B 2,093B P/E 2026 *
-21.7x
P/E 2027 * -62.2x
Enterprise Value 12.73B 11.18B 10.3B 9.63B 18.06B 1,201B 18.39B 124B 47.87B 592B 47.79B 46.74B 2,057B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 8.51x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-0.20%
1 week+6.07%
Current month+833.97%
1 month+833.97%
3 months+833.97%
6 months+833.97%
Current year+833.97%
1 week 65.66
Extreme 65.66
68.6
1 month 62.42
Extreme 62.42
68.6
Current year 62.42
Extreme 62.42
68.6
1 year 62.42
Extreme 62.42
68.6
3 years 62.42
Extreme 62.42
68.6
5 years 62.42
Extreme 62.42
68.6
10 years 62.42
Extreme 62.42
68.6
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+6.07% - - 12.65B
+1.67%+9.28%-5.05%+1.40% 45.45B
+4.95%+9.31%+363.86%+598.16% 36.09B
+0.44%+11.12%+17.47%-12.91% 30.98B
-0.64%+1.92%+3.08%+53.58% 30.81B
+0.23%-0.29%+13.24%+21.10% 24.62B
+9.90%+13.32% - - 14.78B
+1.40%+12.99%+67.11%+132.76% 14.65B
+1.88%+8.59%+13.76%+20.68% 13.3B
+1.76%+10.25%+10.31%-28.88% 12.11B
Average +2.14%+7.23%+60.47%+98.23% 24.75B
Weighted average by Cap. +1.97%+7.02%+72.86%+121.60%

Financials

2026 *2027 *
Net sales 893M 785M 723M 676M 1.27B 84.3B 1.29B 8.68B 3.36B 41.56B 3.36B 3.28B 144B 1.51B 1.32B 1.22B 1.14B 2.14B 142B 2.18B 14.61B 5.66B 70.01B 5.65B 5.53B 243B
Net income -598M -526M -484M -453M -849M -56.47B -865M -5.81B -2.25B -27.84B -2.25B -2.2B -96.73B -199M -174M -161M -150M -282M -18.74B -287M -1.93B -747M -9.24B -746M -729M -32.1B
Net Debt -220M -193M -178M -166M -312M -20.76B -318M -2.14B -828M -10.23B -826M -808M -35.57B -138M -121M -112M -105M -196M -13.04B -200M -1.34B -520M -6.43B -519M -507M -22.33B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-06-25 €68.46 -0.20% 0
26-06-24 €68.60 +1.96% 82
26-06-23 €67.28 +2.47% 105
26-06-22 €65.66 +1.74% 0
26-06-18 €64.54 -0.25% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
78.34USD
Average target price
105.91USD
Spread / Average Target
+35.20%

Quarterly revenue - Rate of surprise